Mavrilimumab
- Generic Name
- Mavrilimumab
- Drug Type
- Biotech
- CAS Number
- 1085337-57-0
- Unique Ingredient Identifier
- 1158JD1P9A
- Background
Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.
Kiniksa Reports Strong ARCALYST Growth, Advances KPL-387 for Recurrent Pericarditis Development
• ARCALYST achieved remarkable growth with $417 million in 2024 net product revenue, representing a 79% year-over-year increase, with projected 2025 revenue between $560-580 million.
• Kiniksa plans to initiate Phase 2/3 clinical trial of KPL-387 for recurrent pericarditis in mid-2025, offering potential monthly subcutaneous dosing option for patients.
• Company announces strategic focus on cardiovascular indications while discontinuing abiprubart development in Sjögren's Disease, maintaining positive cash flow expectations.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath